Safety of erlotinib treatment in outpatients with previously treated non-small-cell lung cancer in Japan

被引：0
|
作者：
Hiroki Nagai
Shiro Tanaka
Miyuki Niimi
Nanae Seo
Takahiko Sasaki
Hiroshi Date
Michiaki Mishima
Hiroyasu Yasuda
Kazuhiro Yanagihara
机构：
[1] Outpatient Oncology Unit,Department of Respiratory Medicine, Graduate School of Medicine
[2] Kyoto University Hospital,Department of Clinical Trial Design and Management, Translational Research Center
[3] Kyoto University,Department of Respiratory Medicine
[4] Kyoto University Hospital,Department of Thoracic Surgery, Graduate School of Medicine
[5] Tohoku University School of Medicine,Department of Clinical Application
[6] Kyoto University,Department of Translational Clinical Oncology, Graduate School of Medicine
[7] Tohoku University Translational Research Center,undefined
[8] Kyoto University,undefined
来源：
International Journal of Clinical Oncology | 2011年 / 16卷
关键词：
Erlotinib; Epidermal growth factor receptor; Epidermal growth factor receptor–tyrosine kinase inhibitor; Adverse events; Non-small-cell lung cancer; Japanese outpatients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer
    Rinaldi, Fiona
    George, Elisabeth
    Clark, Peter
    LANCET ONCOLOGY, 2011, 12 (08): : 728 - 730
  • [22] Effect of Amrubicin in Patients with Previously Treated Non-Small-Cell Lung Cancer
    Takayama, S.
    Tamura, T.
    Kawajiri, T.
    Nishi, T.
    Kudo, K.
    Kuyama, S.
    Kawakado, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [23] Special Report: Policy Erlotinib for the treatment of non-small-cell lung cancer
    Kandaswamy, Prashanth
    Boysen, Meindert
    Longson, Carole
    Stevens, Andrew
    LANCET ONCOLOGY, 2009, 10 (01): : 15 - 16
  • [24] Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer
    Roa, V
    Conner, A
    Mitchell, RB
    CANCER INVESTIGATION, 1998, 16 (06) : 381 - 384
  • [25] Erlotinib in the first-line treatment of non-small-cell lung cancer
    D'Arcangelo, Manolo
    Cappuzzo, Federico
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (05) : 523 - 533
  • [26] CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Park, Sun Hoo
    Park, Jong Heon
    Lee, Jae Cheol
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 247 - 253
  • [27] Initial safety and efficacy results of erlotinib in previously treated patients with advanced non-small cell lung cancer
    Zhou, S.
    Zhou, C.
    Yan, L.
    Xu, Q.
    Xu, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 991 - 997
  • [29] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [30] Erlotinib As Maintenance Monotherapy in Non-Small-Cell Lung Cancer
    Muir, Victoria J.
    Dhillon, Sohita
    BIODRUGS, 2011, 25 (03) : 139 - 146
12345